- Home
- ALXO vs ENLV Comparison
ALXO vs ENLV Comparison
Compare ALXO & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ENLV
- Stock Information
- Founded
- ALXO 2015
- ENLV 2005
- Country
- ALXO United States
- ENLV Israel
- Employees
- ALXO N/A
- ENLV N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- ENLV Health Care
- Exchange
- ALXO Nasdaq
- ENLV Nasdaq
- Market Cap
- ALXO 24.0M
- ENLV 23.7M
- IPO Year
- ALXO 2020
- ENLV 1995
- Fundamental
- Price
- ALXO $0.61
- ENLV $1.56
- Analyst Decision
- ALXO Strong Buy
- ENLV Strong Buy
- Analyst Count
- ALXO 6
- ENLV 2
- Target Price
- ALXO $3.30
- ENLV $10.00
- AVG Volume (30 Days)
- ALXO 500.5K
- ENLV 168.1K
- Earning Date
- ALXO 08-07-2025
- ENLV 08-29-2025
- Dividend Yield
- ALXO N/A
- ENLV N/A
- EPS Growth
- ALXO N/A
- ENLV N/A
- EPS
- ALXO N/A
- ENLV N/A
- Revenue
- ALXO N/A
- ENLV N/A
- Revenue This Year
- ALXO N/A
- ENLV N/A
- Revenue Next Year
- ALXO N/A
- ENLV N/A
- P/E Ratio
- ALXO N/A
- ENLV N/A
- Revenue Growth
- ALXO N/A
- ENLV N/A
- 52 Week Low
- ALXO $0.40
- ENLV $0.81
- 52 Week High
- ALXO $6.08
- ENLV $1.76
- Technical
- Relative Strength Index (RSI)
- ALXO 61.99
- ENLV 70.40
- Support Level
- ALXO $0.44
- ENLV $1.12
- Resistance Level
- ALXO $0.64
- ENLV $1.32
- Average True Range (ATR)
- ALXO 0.04
- ENLV 0.09
- MACD
- ALXO 0.01
- ENLV 0.00
- Stochastic Oscillator
- ALXO 72.40
- ENLV 93.75
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.